Additional dosing, storing, and handling information for CLEVIPREX® (clevidipine)


Learn about CLEVIPREX® (clevidipine)

No experience of overdosage in human clinical trials1

  • Maximum total doses of CLEVIPREX tested in clinical trials were 106 mg/hr or 1,153 mg
  • The expected major effects of overdose would be hypotension and reflex tachycardia

In case of suspected overdosage, CLEVIPREX should be discontinued immediately and the patient’s blood pressure should be supported

  • In most patients, discontinuation of CLEVIPREX leads to full recovery of blood pressure within 5 to 15 minutes

CLEVIPREX is Y-site compatible with several IV bag fluids1

CLEVIPREX is Y-site compatible with several IV fluid bags

Considerations when using a Y-site to administer CLEVIPREX

  • Do not dilute CLEVIPREX
  • Do not administer CLEVIPREX in the same line as other medications

Compatible IV bag fluids include:

  • Water for Injection, USP
  • 0.9% Sodium Chloride Injection, USP
  • 5% Dextrose Injection, USP
  • 5% Dextrose in 0.9% Sodium Chloride Injection, USP
  • 5% Dextrose in Lactated Ringer’s Injection, USP
  • Lactated Ringer’s Injection, USP
  • 10% Amino Acid

Available dosing resources

Keep CLEVIPREX information readily available with a lanyard or hanging dosing card. Contact a Chiesi sales representative to order yours.

Storage and handling considerations for CLEVIPREX1

Light Icon

Light sensitivity

CLEVIPREX is photosensitive; leave vials in cartons until use

  • Protection from light during administration is not required

Temperature Icon

Temperature guidelines

  • Store vials in cartons refrigerated at 2–8 °C (36–46 °F); do not freeze
  • Vials in cartons may be transferred to storage at 25 °C (77 °F, USP controlled room temperature) for up to 2 months
    • Upon transfer to room temperature, mark vials in cartons “This product was removed from the refrigerator on __/__/__ date. It must be used or discarded 2 months after this date or the labeled expiration date (whichever date comes first)”
  • Do not return CLEVIPREX to refrigerated storage after switching to USP controlled room temperature
  • Once stopper is punctured, use within 12 hours and discard any unused portion

Individualized, titratable administration1

CLEVIPREX has a low-volume, non–weight-based dosing regimen that is independent of renal or hepatic function.1

50 mL and 100 mL CLEVIPREX single-use vials

Transitioning off CLEVIPREX

Learn what to consider when transitioning patients off CLEVIPREX.


Demonstrated safety profile

The safety profile of CLEVIPREX was evaluated in multiple clinical trials.1